Our data also provide a functional explanation for recent clinical observations that neutralization of RANKL by denosumab, beyond protection from bone loss, prolongs disease-free survival in patients with solid tumors as observed in breast cancer. The gene discussed is TNFSF11; the disease is breast carcinoma.